Bevacizumab
- Generic Name
- Bevacizumab
- Brand Names
- Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 216974-75-3
- Unique Ingredient Identifier
- 2S9ZZM9Q9V
- Background
There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.
...
- Indication
As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer;...
- Associated Conditions
- Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Colorectal Cancer (CRC), Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Persistent Cervical Cancer, Recurrent Cervical Cancer, Recurrent Glioblastoma, Relapsed Glioblastoma, Stage III Fallopian Tube Cancer, Stage III Ovarian Epithelial Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Recurrent Platinum-resistant Epithelial Ovarian Cancer, Recurrent platinum drug resistant Fallopian tube cancer, Recurrent platinum drug resistant primary peritoneal cancer, Recurrent platinum sensitive primary peritoneal cancer, Recurrent platinum-sensitive fallopian tube cancer, Unresectable Non-Squamous Non-Small Cell Lung Cancer, Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
- Associated Therapies
- First Line Chemotherapy, First or Second Line Therapy, Second Line Treatment
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
- Conditions
- Interventions
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Isala
- Target Recruit Count
- 679
- Registration Number
- NCT06031233
- Locations
- 🇳🇱
Isala Hospital, Zwolle, Netherlands
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 198
- Registration Number
- NCT06023862
- Locations
- 🇰🇷
Bundang Seoul National University Hospital, Seongnam-si, Korea, Republic of
🇰🇷Severance Hospital, Yonsei Health System, Seoul, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT06006286
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab
- Conditions
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Catharina Ziekenhuis Eindhoven
- Target Recruit Count
- 85
- Registration Number
- NCT06003998
- Locations
- 🇳🇱
Catharina Hospital, Eindhoven, Netherlands
🇳🇱Erasmus Medical Centre, Rotterdam, Netherlands
Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 21
- Registration Number
- NCT05999812
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Inspirna, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05983367
- Locations
- 🇧🇪
Imelda Ziekenhuis, Bonheiden, Antwerpen, Belgium
🇧🇪Universite Catholique de Louvain (UCL) - Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, Brussels Capital Region, Belgium
🇧🇪Institut Jules Bordet, Anderlecht, Belgium
A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 668
- Registration Number
- NCT05976568
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
🇨🇳Nanjing Tianyinshan Hospital, Nanjing, Jiangsu, China
Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma With Failure of Systemic Therapy Combined With Interventional Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- HuiKai Li
- Target Recruit Count
- 30
- Registration Number
- NCT05975463
- Locations
- 🇨🇳
Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China
FOG-001 in Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Parabilis Medicines, Inc.
- Target Recruit Count
- 480
- Registration Number
- NCT05919264
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Shanghai Kanda Biotechnology Co., Ltd.
- Target Recruit Count
- 85
- Registration Number
- NCT05906524
- Locations
- 🇨🇳
Zhongshan Hospital, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.